• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
| Market Cap | 2.194 Billion | Shares Outstanding | 32.27 Million | Avg 30-day Volume | 508.822 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.38 |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | 0 |
| Price to Book Value | 3.4623 | Operating Margin | 0.0 | Enterprise Value | 375.25 Million |
| Current Ratio | 18.866 | EPS Growth | 0 | Quick Ratio | 18.055 |
| 1 Yr BETA | 1.2374 | 52-week High/Low | 0.0 / | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 0.0 | Altman Z-Score | 27.1601 | Free Cash Flow to Firm | 0 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2020-01-23 | 0 | |
|
No longer subject to file | 2020-01-23 | 0 | |
|
0 | 2020-01-23 | 0 | |
|
No longer subject to file | 2020-01-23 | 0 | |
|
No longer subject to file | 2020-01-23 | 0 | |
|
No longer subject to file | 2020-01-23 | 0 | |
|
SHAWVER LAURA PRESIDENT AND CEO |
|
No longer subject to file | 2020-01-23 | 0 |
|
No longer subject to file | 2020-01-23 | 0 | |
|
LEVEQUE JOSEPH CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2020-01-23 | 0 |
|
REARDON TIGHE ACTING CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2020-01-23 | 0 |
|
MILLA MARCOS CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2020-01-23 | 0 |
|
No longer subject to file | 2020-01-14 | 0 | |
|
0 | 2019-06-07 | 0 | |
|
5,316,355 | 2018-12-11 | 0 | |
|
16,428,976 | 2018-12-11 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
